相关实验视频

Updated: Jul 20, 2025

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Published on: May 19, 2022

COVID-19感染和疫苗接种及其与氨基粉症的关系:我们目前知道什么?

Wing-Yin Leung¹, Henry H L Wu², Lauren Floyd^1,3

¹Department of Renal Medicine, Lancashire Teaching Hospitals NHS Foundation Trust, Preston PR2 9HT, UK.

|July 29, 2023

概括

氨基化症涉及蛋白质错误折叠,可以由炎症或COVID-19等病毒感染引发. 目前正在进行研究,以澄清COVID-19,疫苗接种和粉样性粉症发展或复发之间的联系.

科学领域:

免疫学免疫学免疫学
病理学病理学病理学
病毒学病毒学

背景情况:

氨基粉症是一种错误折叠,沉积蛋白质的疾病,通常与慢性炎症 (AA氨基粉症) 和多器官功能障碍有关.
严重急性呼吸道综合征冠状病毒2 (COVID-19) 呈现出类似于粉样蛋白症的肺外表现,包括氧化应激,炎症和血栓形成.
众所周知,病毒性疾病是导致自身免疫性疾病的触发因素,包括粉样粉症,最近有报道将COVID-19感染和接种疫苗与新发病或复发疾病联系起来.

研究的目的:

对有关粉样化症,COVID-19感染和COVID-19疫苗接种之间的关联的现有证据进行范围审查.
评估当前关于COVID-19和氨基粉症之间的病理生理学联系的观点.
识别需要未来研究的知识差距.

主要方法:

系统地搜索可用的文献.
覆盖范围审查方法.
评估当前的证据和观点.

主要成果:

有证据表明,COVID-19 (感染和接种疫苗) 与粉样性粉症之间存在潜在联系,包括新发病和复发病例.
在这两种情况中都观察到共享的病理生理特征,如慢性炎症和氧化应激.
推动这些协会的确切机制尚不清楚.

结论:

COVID-19和粉样粉症之间的关系需要进一步调查.
了解这些联系对于在流行病背景下管理amyloidosis患者至关重要.
需要进一步的研究来阐明精确的病理生理路径,并为临床实践提供信息.

关键词:

在 COVID-19 疫情中,接种COVID-19疫苗的时间氨基粉症是什么?结果就是结果.病理生理学病理生理学

更多相关视频

Rapid Generation of Amyloid from Native Proteins In vitro

Rapid Generation of Amyloid from Native Proteins In vitro

Published on: December 5, 2013

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

相关概念视频

Amyloid Fibrils

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...